CNTA - Centessa Pharmaceuticals PLC ADR
Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US1523091007
Hemophilia, Narcolepsy, Sleep Disorders, Solid Tumors
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to improve patients' lives.
The company's pipeline is built around several promising products, including SerpinPC, an activated protein C inhibitor designed to treat hemophilia A and B, two genetic disorders that affect the blood's ability to clot. Another key product is ORX750, an orally administered OX2R agonist that targets the treatment of narcolepsy, a chronic sleep disorder, as well as other sleep-related conditions.
Centessa is also working on LB101, a bi-specific monoclonal antibody that aims to treat solid tumors by selectively driving potent CD47 and CD3 effector function activity while minimizing systemic toxicity. This approach has the potential to revolutionize cancer treatment by targeting specific cancer cells while sparing healthy cells.
In addition to these products, the company is developing other OX2R Agonists compounds to treat narcolepsy, as well as earlier-stage preclinical assets and discovery-stage programs. This diversified pipeline positions Centessa to make a significant impact in the pharmaceutical industry.
Founded in 2020, Centessa Pharmaceuticals plc is headquartered in Altrincham, the United Kingdom, and is committed to advancing its pipeline through rigorous research and development. For more information, visit their website at https://www.centessa.com.
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for CNTA - Centessa Pharmaceuticals PLC ADR](https://www.valueray.com/images/drawdown_chart/CNTA.NASDAQ_drawdown.png)
Overall Trend and Yearly Seasonality
![Drawdown / Underwater Chart for CNTA - Centessa Pharmaceuticals PLC ADR](https://www.valueray.com/images/chart/CNTA.NASDAQ_seasonality.png)
CNTA Stock Overview
Market Cap in USD | 1,456m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2021-05-28 |
CNTA Stock Ratings
Growth 5y | -13.1 |
Fundamental | - |
Dividend | 0.00 |
Rel. Performance vs Sector | 2.86 |
Analysts | 4.57/5 |
Fair Price Momentum | 17.81 USD |
Fair Price DCF | - |
CNTA Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
CNTA Growth Ratios
Growth 12m | 121.36% |
Growth Correlation 12m | 79% |
Growth Correlation 3m | 90% |
CAGR 5y | -11.99% |
CAGR/Mean DD 5y | -0.18 |
Sharpe Ratio 12m | 1.61 |
Alpha vs SP500 12m | 105.55 |
Beta vs SP500 5y weekly | 0.60 |
ValueRay RSI | 93.20 |
Volatility GJR Garch 1y | 80.60% |
Price / SMA 50 | 29.53% |
Price / SMA 200 | 50.21% |
Current Volume | 150.6k |
Average Volume 20d | 478.5k |
External Links for CNTA Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of September 08, 2024, the stock is trading at USD 14.30 with a total of 150,556 shares traded.
Over the past week, the price has changed by +5.93%, over one month by +33.02%, over three months by +60.31% and over the past year by +117.99%.
According to ValueRays Forecast Model, CNTA Centessa Pharmaceuticals PLC ADR will be worth about 19.6 in September 2025. The stock is currently trading at 14.30. This means that the stock has a potential upside of +36.85%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 14.5 | 1.40 |
Analysts Target Price | 8.8 | -38.5 |
ValueRay Target Price | 19.6 | 36.9 |